MedTrace Logo

Non-intrusive Detection of Temporary Neurologic Impairment By Opioids

NCT04223609 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2023-04-05

Study results available
· View outcomes & findings →

Summary

Research is being conducted to better understand the physiologic effects (relating to the action of a drug when taken by a healthy person) of opioid use on oculomotor (relating to the motion of the eye) dynamics and to identify the presence of characteristics consistent with a specific drug or class of drugs.

Conditions

  • Healthy

Interventions

DRUG

Oxycodone

5 mg tablet

DRUG

Placebo

Oxycodone-matched placebo tablet

DEVICE

EyeLink 1000 Plus

Non-invasive video-based eye tracking system

DIAGNOSTIC_TEST

Oculo-Cognitive Addition test (OCAT)

Subject will have to look for numbers on a screen and add these numbers together. OCAT will be presented on a computer screen with attached eye tracking device at the bottom part.

DEVICE

VT3mini - Eye Tracking Technology for OEMs

Non-invasive eye-tracking device

Sponsors & Collaborators

Principal Investigators

  • Gaurav Pradhan, PhD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-28
Primary Completion
2022-04-11
Completion
2022-04-11
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04223609 on ClinicalTrials.gov